Thor Medical - Småprat '22 (NANOV) 4

[TekBot]

Thor Medical ASA - Share capital increase in relation to the Private Placement and the PrimaryBid Offering is registered

26.6.2025 14:24:32 CEST | Thor Medical ASA | Total number of voting rights and
capital

…

Vis børsmeldingen

Oslo, Norway, 26 June 2025: Reference is made to stock exchange announcement by
Thor Medical ASA (the “Company”) on 18 June 2025 regarding the successful
completion of a private placement of a total of 30,000,000 new shares in the
Company raising a total of NOK 75 million in gross proceeds (the “Private
Placement”) and a retail offering of a total of 4,577,399 new shares raising a
total of approx. NOK 11.4 million in gross proceeds (the “PrimaryBid Offering”).

The share capital increase relating to the Private Placement and the share
capital increase relating to the PrimaryBid Offering is now registered with the
Norwegian Register of Business Enterprises. The Company’s share capital is after
the registration NOK 69,797,184 divided into 348,985,920 shares. Each share has
a nominal value of NOK 0.20 and represents one vote in the Company’s general
meeting.

DISCLOSURE REGULATION

This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.

CONTACTS

Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18581837/6253/Download%20announce
ment%20as%20PDF.pdf

Kilde

[TekBot]

Thor Medical ASA: Primary insider notification and disclosure of large shareholdings

26.6.2025 14:33:26 CEST | Thor Medical ASA | Major shareholding notifications

Oslo, Norway, 26 June 2025: Reference is made to the stock exchange
…

Vis børsmeldingen

announcements by Thor Medical ASA (the “Company”) on 18 June 2025 regarding the
successful completion of a private placement of new shares (the “Private
Placement”) raising gross proceeds of approximately NOK 75 million and a retail
offering of new shares (the “PrimaryBid Offering”) raising gross proceeds of
approximately NOK 11.4 million, and the disclosure of large shareholding
notification on 18 June 2025 regrading, inter alia, the effectuation of a share
loan under a share lending agreement entered into by and between the Company,
its shareholder Scatec Innovation AS as share lender and Arctic Securities AS
and DNB Carnegie, a part of DNB Bank ASA, as managers (the “Managers”), to
facilitate delivery-versus-payment settlement in the Privat Placement and the
PrimaryBid Offering (the “Share Lending Agreement”).

Today, following registration of the share capital increases pertaining to the
Private Placement and the PrimaryBid Offering, the Managers will redeliver
31,577,399 new shares in the Company to Scatec Innovation AS pursuant to the
Share Lending Agreement. Following the effectuation of the redelivery of
31,577,399 new shares in the Company and the delivery of 3,000,000 new shares
allocated to Scatec Innovation AS in the Private Placement, Scatec Innovation
AS’ holding of shares in the Company will be 81,419,309, equivalent to approx.
23.3% of the issued share capital and votes. Consequently, Scatec Innovation AS
will cross above the 15% and 20% thresholds pursuant to section 4-2 (1) and (3)
of the Norwegian Securities Trading Act.

In addition, Scatec Innovation AS has controlling interest in Scatec Invest IV
AS, which holds 354,453 shares in the Company. Scatec Innovation AS aggregated
holding of shares is thus 81,773,762, equivalent to approx. 23.4% of the shares
and votes in the Company.

Scatec Innovation AS is a close associate of chairman John Andersen. Primary
insider notification pursuant to the market abuse regulation article 19 is
attached.

This announcement is published in accordance with section 4-2 of the Norwegian
Securities Trading Act and is subject to disclosure requirements pursuant to the
EU Market Abuse Regulation article 19 (3) and the Norwegian Securities Trading
Act section and 5-12.

Contacts

Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.

To learn more, visit www.thormedical.com - http://www.thormedical.no

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18581841/6255/Download%20announce
ment%20as%20PDF.pdf

20250626 - Primary insider notifications Scatec Innovation AS.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18581841/6254/20250626%20-%20Prim
ary%20insider%20notifications%20Scatec%20Innovation%20AS.pdf

Kilde

[agobkf1378]

Tillater meg å sitere dette fra FB:
HENTET FRA REP EMI PROSPEKTET. SE BEKREFTELSE PÅ STRATEGISK MÅL FOR 2030 og 2035!!! 250.000 doser innen 5 år, og 1 mill doser innen 10 år-Alpha One er KUN starten, og IKKE der potensialet ligger. Det er uttalt ca 15.000 kr pr dose.
Dere kan jo begynne regne på caset med utgangspunkt 50% margin som oppgitt fra selskapet, og en vekst multippel på x 10. Med 3 mrd i fremførbart underskudd blir det noen år uten skatt
Verdivurderingen på TP 4 nok fra Artic dreier seg om KUN Alpha One UTEN 40% kapasitetsøkning som nå er varslet. Den 40% kapasitetsøkningen utgjør KUN 10% utvanning for aksjonærene som ikke tegner seg.

Fra prospektet:
As referred to in Section 2.1 above, the Company completed the Private Placement and the PrimaryBid Offer in order to fund increased capacity at its AlphaOne plant currently under construction by approximately 40%. The planned capacity increase at AlphaOne will take place within the original construction timeline and allow for AlphaOne to be fully operational by the end of the third quarter 2026. Planned production capacity after three years of operation is expected to increase from 15,000 patient doses to 21,000 doses. 4.3 Strategy of the Group and principal markets Thor Medical aims to become a world leading supplier of alpha-emitters for the radiopharmaceutical industry, enabling next generation precision cancer therapy. Cancer is a leading cause of death worldwide, accounting for around 10 million deaths per year as of 20201, with radiotherapeutics representing one of the fastest growing options for cancer treatment2. The radiopharmaceutical industry is increasingly focusing on Targeted Alpha Therapy, utilizing the high energy deposition and short range of alpha particle emitters to eradicate cancer cells while minimizing damage to healthy cells. The commercial market opportunity for radiotherapeutics is expected to reach USD 27 billion by 2032.3 As mentioned in Section 4.2, Thor Medical has recently completed construction of pilot facilities for manufacturing of alpha-emitters at Herøya, Norway. The pilot facilities will be the basis for verifying product and process, deliver product samples to customers, and serve as platform for scale-up to commercial production. Going forward, the Company expects to enter into sales agreements with customers subject to quality acceptance of product samples, providing a commercial fundament for an investment decision for a commercial scale production facility. Thor Medical’s customers are indicating a significantly increased and rapidly growing demand for alpha-emitters and the ambition is to establish a position as a leading and reliable long-term supplier to these customers. Thor Medical’s goal is to bring to market industrial scale production capacity enabling delivery of more than 250,000 patient doses by 2030. Beyond 2030, the Company aims for further global industrialisation and a capacity increase towards delivery capacity of more than 1,000,000 patient doses by 2035.

Det er viktig å merke seg : Company expect to enter into sales agreement with customers SUBJECT TO QUALITY ACCEPTANCE OF PRODUCT SAMPLES.
Det er fremdeles usikkert om kvaliteten er tilfredsstillende for markedet. En utfordring som må løses for at det skal bli success.

[Pk2k]

@agobkf1378

Det er fremdeles usikkert om kvaliteten er tilfredsstillende for markedet. En utfordring som må løses for at det skal bli success.

Tviler på at det er noe feil med kvaliteten, hadde ikke solgt ut kapasiteten om det var tilfellet.

[agobkf1378]

Subject to quality acceptance!!
Klar tale!!

[Pk2k]

Sånne klausuler finner du i alle prospekter/avtaler. Betyr ikke at det er noe å bekymre seg over.

[agobkf1378]

Ok - så du mener det er vanlig i bransjen - det er beroligende. De har jo inngått to store avtaler med ukjent men betydelig store aktører og - der kvaliteten er tilfredsstillende.

[Hotdog]

Er prisen pr aksje i rep emien 2,5kr?

[Bingo123]

@agobkf1378

Subject to quality acceptance

Gjelder ikke Subject to quality acceptance for de to avtalene ?
Der er alt ok ?

[agobkf1378]

Jo - produksjonen er vel ikke gjennomført enda. Men har forstått at prøve produksjonen på Herøya gir gode kvaliteter - så får vi satse på at de har kontroll på den.

[TekBot]

Thor Medical ASA: The Subscription Period in the Subsequent Offering ends at 16:30 CEST today

3.7.2025 07:00:01 CEST | Thor Medical ASA | Additional regulated information
required to be disclosed under the laws of a member state

…

Vis børsmeldingen

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS,
ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE
“UNITED STATES”), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION
OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH
THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

Oslo, 3 July 2025. Reference is made to the announcement by Thor Medical ASA
(the “Company”) on 25 June 2025 regarding commencement of the subscription
period in the subsequent offering of up to 4,000,000 new shares in the Company
(the “Offer Shares”) at a subscription price of NOK 2.50 per share (the
“Subsequent Offering”).

The subscription period for the Subsequent Offering (the “Subscription Period”)
will expire at 16:30 CEST today, 3 July 2025.

Correctly completed subscription forms must be received by one of the Managers
(as defined below) or, in the case of online subscriptions, be registered before
16:30 CEST today, 3 July 2025.

Subscription rights that are not used to subscribe for Offer Shares in the
Subsequent Offering before the expiry of the Subscription Period will have no
value and will lapse without compensation to the holder.

Further information about the Subsequent Offering and the subscription
procedures is included in the national prospectus dated 25 June 2025 (the
“Prospectus”), which is available at the websites of the Managers (as defined
below) https://www.arctic.com/offerings and https://www.dnb.no/emisjoner -
Pågående emisjoner | DNB Carnegie.

The Prospectus is a national prospectus (Nw. nasjonalt prospekt) and neither the
Financial Supervisory Authority of Norway (Nw. Finanstilsynet) nor any other
public authority has carried out any form of review, control or approval of the
Prospectus. The Prospectus does not constitute an EEA-prospectus, as defined in
section 7-1 of the Norwegian Securities Trading Act. Subscriptions for Offer
Shares may only be made on the basis of the Prospectus and the subscription
form.

Arctic Securities AS and DNB Carnegie, a part of DNB Bank ASA are acting as
managers (the “Managers”) in the Subsequent Offering. Advokatfirmaet Selmer AS
is acting as legal advisor to Thor Medical ASA.

Contacts

Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.

To learn more, visit www.thormedical.com. - http://www.thormedical.no

This information is published in accordance with the requirements of the
Continuing Obligations for companies listed on Euronext Oslo Børs and section
5-12 of the Norwegian Securities Trading Act.

Important notice

This announcement is not and does not form a part of any offer to sell, or a
solicitation of an offer to purchase, any securities of the Company. Copies of
this announcement are not being made and may not be distributed or sent into any
jurisdiction in which such distribution would be unlawful or would require
registration or other measures.

The securities referred to in this announcement have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the “Securities
Act”), and accordingly may not be offered or sold in the United States absent
registration or an applicable exemption from the registration requirements of
the Securities Act and in accordance with applicable U.S. state securities laws.
The Company does not intend to register any part of the offering in the United
States or to conduct a public offering of securities in the United States. Any
sale in the United States of the securities mentioned in this announcement will
be made solely to “qualified institutional buyers” as defined in Rule 144A under
the Securities Act.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State. The expression “Prospectus
Regulation” means (EU) 2017/1129 of the European Parliament and of the Council,
of 14 June 2017, as amended Regulation, on the prospectus to be published when
securities are offered to the public (together with any applicable implementing
measures in any EEA Member State.

This communication is only being distributed to and is only directed at persons
in the United Kingdom that are (i) investment professionals falling within
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended (the “Order”) or (ii) high net worth entities,
and other persons to whom this announcement may lawfully be communicated,
falling within Article 49(2)(a) to (d) of the Order (all such persons together
being referred to as “relevant persons”). This communication must not be acted
on or relied on by persons who are not relevant persons. Any investment or
investment activity to which this communication relates is available only for
relevant persons and will be engaged in only with relevant persons. Persons
distributing this communication must satisfy themselves that it is lawful to do
so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “believe”, “expect”, “anticipate”,
“strategy”, “intends”, “estimate”, “will”, “may”, “continue”, “should” and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believe that these assumptions were reasonable
when made, these assumptions are inherently subject to significant known and
unknown risks, uncertainties, contingencies and other important factors which
are difficult or impossible to predict, and are beyond their control. Actual
events may differ significantly from any anticipated development due to a number
of factors, including without limitation, changes in public sector investment
levels, changes in the general economic, political and market conditions in the
markets in which the Company operates, the Company’s ability to attract, retain
and motivate qualified personnel, changes in the Company’s ability to engage in
commercially acceptable acquisitions and strategic investments, and changes in
laws and regulation and the potential impact of legal proceedings and actions.
Such risks, uncertainties, contingencies and other important factors could cause
actual events to differ materially from the expectations expressed or implied in
this release by such forward-looking statements. The Company does not make any
guarantee that the assumptions underlying the forward-looking statements in this
announcement are free from errors nor does it accept any responsibility for the
future accuracy of the opinions expressed in this announcement or any obligation
to update or revise the statements in this announcement to reflect subsequent
events. You should not place undue reliance on the forward-looking statements in
this announcement.

The information, opinions and forward-looking statements contained in this
announcement speak only as at its date, and are subject to change without
notice. The Company does not undertake any obligation to review, update,
confirm, or to release publicly any revisions to any forward-looking statements
to reflect events that occur or circumstances that arise in relation to the
content of this announcement.

Neither the Managers nor any of their affiliates makes any representation as to
the accuracy or completeness of this announcement and none of them accepts any
responsibility or liability for the contents of this announcement or any matters
referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of its affiliates accepts any liability arising from the use of
this announcement.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18589434/6271/Download%20announce
ment%20as%20PDF.pdf

Kilde

[TekBot]

Thor Medical ASA: Final results of the Subsequent Offering

4.7.2025 10:41:40 CEST | Thor Medical ASA | Additional regulated information
required to be disclosed under the laws of a member state

…

Vis børsmeldingen

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS,
ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE
“UNITED STATES”), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION
OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH
THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

Oslo, 4 July 2025. Reference is made to the announcement by Thor Medical ASA
(the “Company”) on 26 June 2025 regarding commencement of the subscription
period in the subsequent offering of up to 4,000,000 new shares in the Company
(the “Offer Shares”) at a subscription price of NOK 2.50 per share (the
“Subsequent Offering”). The subscription period in the Subsequent Offering (the
“Subscription Period”) expired on 3 July 2025 at 16:30 hours (CEST). By the end
of the Subscription Period, the Subsequent Offering was oversubscribed.

The Company’s board of directors has today approved an allocation and resolved
the issuance of 4,000,000 Offer Shares pursuant the authorization to increase
the Company’s share capital granted by the Company’s annual general meeting held
on 24 April 2025, and in accordance with the allocation criteria set out in the
national prospectus and the subscription form published in connection with the
Subsequent Offering.

The Company will consequently raise NOK 10 million in gross proceeds through the
Subsequent Offering. Investors that are allocated Offer Shares can access
information on the number of Offer Shares allocated through VPS. The due date
for payment of the Offer Shares is on 8 July 2025.

Subject to duly and timely payment of the Offer Shares, the share capital
increase is expected to be registered in the Norwegian Register of Business
Enterprises on or about 11 July 2025 and will be delivered to the VPS accounts
of the subscribers shortly thereafter, expected on or about 15 July 2025. A
separate announcement will be made when the share capital increase has been
registered in Norwegian Register of Business Enterprises. The Offer Shares will
have equal rights and rank pari passu with the Company’s other shares.

Arctic Securities AS and DNB Carnegie, a part of DNB Bank ASA are acting as
managers (the “Managers”) in the Subsequent Offering. Advokatfirmaet Selmer AS
is acting as legal advisor to Thor Medical ASA.

Contacts

Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.

To learn more, visit www.thormedical.com - http://www.thormedical.no

This information is published in accordance with the requirements of the
Continuing Obligations for companies listed on Euronext Oslo Børs and section
5-12 of the Norwegian Securities Trading Act.

Important Notices

This announcement is not and does not form a part of any offer to sell, or a
solicitation of an offer to purchase, any securities of the Company. Copies of
this announcement are not being made and may not be distributed or sent into any
jurisdiction in which such distribution would be unlawful or would require
registration or other measures.

The securities referred to in this announcement have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the “Securities
Act”), and accordingly may not be offered or sold in the United States absent
registration or an applicable exemption from the registration requirements of
the Securities Act and in accordance with applicable U.S. state securities laws.
The Company does not intend to register any part of the offering in the United
States or to conduct a public offering of securities in the United States. Any
sale in the United States of the securities mentioned in this announcement will
be made solely to “qualified institutional buyers” as defined in Rule 144A under
the Securities Act.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State. The expression “Prospectus
Regulation” means (EU) 2017/1129 of the European Parliament and of the Council,
of 14 June 2017, as amended Regulation, on the prospectus to be published when
securities are offered to the public (together with any applicable implementing
measures in any EEA Member State.

This communication is only being distributed to and is only directed at persons
in the United Kingdom that are (i) investment professionals falling within
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended (the “Order”) or (ii) high net worth entities,
and other persons to whom this announcement may lawfully be communicated,
falling within Article 49(2)(a) to (d) of the Order (all such persons together
being referred to as “relevant persons”). This communication must not be acted
on or relied on by persons who are not relevant persons. Any investment or
investment activity to which this communication relates is available only for
relevant persons and will be engaged in only with relevant persons. Persons
distributing this communication must satisfy themselves that it is lawful to do
so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “believe”, “expect”, “anticipate”,
“strategy”, “intends”, “estimate”, “will”, “may”, “continue”, “should” and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believe that these assumptions were reasonable
when made, these assumptions are inherently subject to significant known and
unknown risks, uncertainties, contingencies and other important factors which
are difficult or impossible to predict, and are beyond their control. Actual
events may differ significantly from any anticipated development due to a number
of factors, including without limitation, changes in public sector investment
levels, changes in the general economic, political and market conditions in the
markets in which the Company operates, the Company’s ability to attract, retain
and motivate qualified personnel, changes in the Company’s ability to engage in
commercially acceptable acquisitions and strategic investments, and changes in
laws and regulation and the potential impact of legal proceedings and actions.
Such risks, uncertainties, contingencies and other important factors could cause
actual events to differ materially from the expectations expressed or implied in
this release by such forward-looking statements. The Company does not make any
guarantee that the assumptions underlying the forward-looking statements in this
announcement are free from errors nor does it accept any responsibility for the
future accuracy of the opinions expressed in this announcement or any obligation
to update or revise the statements in this announcement to reflect subsequent
events. You should not place undue reliance on the forward-looking statements in
this announcement.

The information, opinions and forward-looking statements contained in this
announcement speak only as at its date, and are subject to change without
notice. The Company does not undertake any obligation to review, update,
confirm, or to release publicly any revisions to any forward-looking statements
to reflect events that occur or circumstances that arise in relation to the
content of this announcement.

Neither the Managers nor any of their affiliates makes any representation as to
the accuracy or completeness of this announcement and none of them accepts any
responsibility or liability for the contents of this announcement or any matters
referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of its affiliates accepts any liability arising from the use of
this announcement.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18591801/6280/Download%20announce
ment%20as%20PDF.pdf

Kilde

[TekBot]

Thor Medical ASA - Share capital increase in relation to Subsequent Offering is registered

1.8.2025 08:58:53 CEST | Thor Medical ASA | Total number of voting rights and
capital

…

Vis børsmeldingen

Oslo, Norway, 1 August 2025: Reference is made to stock exchange announcements
by Thor Medical ASA (the “Company”) on 18 June 2025 regarding the completion of
the subsequent offering of a total of 4,000,000 new shares in the Company
raising a total of NOK 10 million in gross proceeds (the “Subsequent Offering”).

The share capital increase relating the Subsequent Offering is now registered
with the Norwegian Register of Business Enterprises. The Company’s share capital
is after the registration NOK 70,597,184 divided into 352,985,920 shares. Each
share has a nominal value of NOK 0.20 and represents one vote in the Company’s
general meeting.

DISCLOSURE REGULATION

This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.

CONTACTS

Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18606641/6332/Download%20announce
ment%20as%20PDF.pdf

Kilde

[TekBot]

Thor Medical and AdvanCell expand strategic supply agreement for Thorium-228

4.8.2025 07:30:00 CEST | Thor Medical ASA | Inside information

Oslo, 4 August 2025: Thor Medical ASA, a leading emerging supplier of
…

Vis børsmeldingen

alpha-emitters for next-generation precision cancer treatment, has expanded its
strategic master supply agreement with AdvanCell, a leading radiopharmaceutical
company with an extensive clinical development program for innovative cancer
therapies.

The new agreement effectively increases the supply of Thorium-228 to AdvanCell
by 50% and the total purchasing commitment from NOK 100 million to NOK 150
million over five years. The increase is enabled by the decision to expand the
capacity at the AlphaOne plant under construction by up to 40%, which will be
financed with proceeds from the capital raise executed by Thor Medical earlier
in June.

“We are working hard to increase capacity at AlphaOne, and it is great to be
able to meet AdvanCell’s increasing demand as they progress their exciting
clinical development programs, including the most advanced Lead-212 PSMA
program,” says Jasper Kurth, CEO of Thor Medical.

Thor Medical and AdvanCell first entered into a strategic supply agreement in
December 2024, following successful sample deliveries to AdvanCell from Thor
Medical’s pilot plant at Herøya.

“Coincident with the rapid enrolment of our TheraPb Phase 1/2 trial
investigating ADVC001 in our Lead-212 PSMA targeted prostate cancer clinical
program - now at a pace of treating up to five patients a week at 200MBq doses -
the scale up of our network of Pb-212 production is also accelerating”, said
Andrew Adamovich, CEO of AdvanCell, continuing “Anticipating the imminent jump
in Lead-212 demand for later stage clinical trials, and ultimately for
commercial scale drug manufacturing, we turn to Thor Medical as a trusted
partner with a similar drive to bring targeted alpha therapies to patients as
quickly as possible. Our aim for ADVC001 is to be amongst the first
PSMA-targeted alpha therapies approved for prostate cancer”.

AdvanCell has a broad pipeline of innovative cancer therapies based on Lead-212
and produces the isotope from precursor Thorium-228 via a proprietary Lead-212
generator-based manufacturing platform. Amongst other pipeline assets, the
company has the most advanced Lead-212 PSMA for prostate cancer. It has a
growing demand for Thorium-228 as it progresses its trial and the rest of its
pipeline.

In February 2025, AdvanCell and Lilly announced a strategic collaboration,
combining AdvanCell’s radionuclide expertise and development infrastructure with
Lilly’s pharmaceutical and oncology expertise and global scale. This
collaboration is intended to accelerate the advancement of an expanded portfolio
of targeted alpha therapies, which in turn is expected to further increase
demand for Thorium-228 as part of a reliable radionuclide value chain.

CONTACT

Thor Medical Brede Ellingsæter, CFO & COO, +47 472 38 440,
brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of alpha particle emitters produced from
naturally occurring thorium. Its proprietary production process requires no
irradiation or use of nuclear reactors, and provides reliable, environmentally
friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical
industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange under the ticker symbol ‘TRMED’.

ABOUT ADVANCELL

AdvanCell is committed to developing innovative targeted alpha therapies that
will change the course of cancer treatment. AdvanCell is the leading
212Pb-focused radiopharmaceutical company and recognised leader in the Targeted
Alpha Therapy field. By combining advanced manufacturing capabilities with
cutting-edge science and clinical development, AdvanCell aims to deliver novel
treatments that enhance outcomes for cancer patients worldwide. For more
information, visit www.advancell.com.au - http://www.advancell.com.au.

Recent news and articles relating to the TheraPb (NCT05720130) Phase 1b study
with ADVC001 can be found here:

TheraPb Phase 1b abstract accepted for presentation at ESMO 2025 -
https://www.advancell.com.au/news/therapb-phase-1b-abstract-accepted-for-present
ation-at-esmo-2025/

AdvanCell presenting at the American Association for Cancer Research (AACR)
Annual Meeting 2025 - AdvanCell -
https://www.advancell.com.au/news/advancell-presenting-at-the-american-associati
on-for-cancer-research-aacr-annual-meeting-2025/

TheraPb highlighted in PSMA Theranostics session at SNMMI by investigator David
Pattison - AdvanCell -
https://www.advancell.com.au/news/therapb-highlighted-in-psma-theranostics-sessi
on-at-snmmi-by-investigator-david-pattison/

Pb212 PSMA vs Ac225 PSMA from biology to supply Alfred Morgenstern PhD Joint
Research Centre Karlsruhe Germany -
https://www.advancell.com.au/news/pb212-psma-vs-ac225-psma-from-biology-to-suppl
y-alfred-morgenstern-phd-joint-research-centre-karlsruhe-germany/

IMPORTANT INFORMATION

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to Section 5-12 the Norwegian Securities Trading Act. The stock
exchange announcement was published by Brede Ellingsæter, CFO & COO, Thor
Medical ASA, at the time and date stated above in this announcement. This
release contains forward -looking information and statements relating to the
business, performance, and matters that may impact the results of Thor Medical.
Forward-looking statements are statements that are not historical facts and may
be identified by words such as “aims,” “anticipates,” “believes,” “estimates,”
“expects,” “foresees,” “intends,” “plans,” “predicts,” “projects,” “targets,”
“potential,” and similar expressions. Such forward-looking statements are based
on current expectations, estimates, and projections, reflect current views
concerning future events, and are subject to risks, uncertainties, and
assumptions, and may be subject to change without notice. Forward-looking
statements are not guarantees of any future performance, and risks,
uncertainties, and other important factors could cause the actual business,
performance, results, or the industry and markets in which Thor Medical operates
to differ materially from the statements expressed or implied in this release by
such forward-looking statements. No representation is made that any of these
forward-looking statements or forecasts will come to pass or that any forecasted
performance, capacities, or results will be achieved, and you are cautioned not
to place any undue reliance on any forward-looking statements. This release is
for information purposes only and is not to be relied upon in substitution for
the exercise of independent judgment. It is not intended as investment advice
and under no circumstances is it to be used or considered as an offer to sell,
or a solicitation of an offer to buy any securities or a recommendation to buy
or sell any securities of the Company.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18607715/6333/Download%20announce
ment%20as%20PDF.pdf

Kilde

[Hennes]

Hvor er Eddie Berglund, når vi trenger en skikkelig grundig analyse av fremtiden til Thor Medical?

[Ceara]

Hvor mye ledig kapasitet av produksjonen på AlphaOne har Trmed etter siste kontraktinngåelse?

[hybrid]

Hva skjedde nå da?

[Georg]

Noen som har sittet på gjerdet som plutselig følte for å handle litt tro?

[Georg]

“TRMED PORTIA AS Ut av listen” De lå vel inne med en større pott. Vil anta at de har tatt en fortjeneste?

Portia AS er en del av Rasmussengruppen.

[hybrid]

De er helt ute. Portia AS 0 aksjer.

Det som er litt rart er at JP Morgan securities lå inne med 300k aksjer 14/8 - 15/8 er det økt til rundt millionen uten at listene har fanget opp en transaksjon.

@pdx - hva er grunnen til det?

neida, så joda. det gikk jo fort.

Ser ut som noen gafler aksjer i dag også gitt.